A detailed history of Hunting Hill Global Capital, LLC transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Hunting Hill Global Capital, LLC holds 13,222 shares of DCTH stock, worth $124,154. This represents 0.12% of its overall portfolio holdings.

Number of Shares
13,222
Previous 5,300 149.47%
Holding current value
$124,154
Previous $44,000 170.45%
% of portfolio
0.12%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.36 - $11.0 $406,124 - $606,980
-55,180 Reduced 80.67%
13,222 $119,000
Q2 2024

Jul 17, 2024

SELL
$4.47 - $8.37 $160,902 - $301,286
-35,996 Reduced 34.48%
68,402 $572,000
Q1 2024

May 15, 2024

SELL
$3.72 - $5.09 $224,866 - $307,680
-60,448 Reduced 36.67%
104,398 $497,000
Q4 2023

Feb 14, 2024

BUY
$2.25 - $4.17 $6,554 - $12,147
2,913 Added 1.8%
164,846 $685,000
Q3 2023

Nov 14, 2023

BUY
$3.12 - $5.85 $505,230 - $947,308
161,933 New
161,933 $655,000

Others Institutions Holding DCTH

About DELCATH SYSTEMS, INC.


  • Ticker DCTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 8,597,680
  • Market Cap $80.7M
  • Description
  • Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...
More about DCTH
Track This Portfolio

Track Hunting Hill Global Capital, LLC Portfolio

Follow Hunting Hill Global Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hunting Hill Global Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hunting Hill Global Capital, LLC with notifications on news.